601. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients.
- Author
-
Kondo S, Horikawa T, Takeshita H, Kanegane C, Kasahara Y, Sheen TS, Sato H, Furukawa M, and Yoshizaki T
- Subjects
- Herpesvirus 4, Human genetics, Herpesvirus 4, Human immunology, Humans, Immunoglobulin A blood, Immunoglobulin G blood, Neoplasm Recurrence, Local, ROC Curve, Antibodies, Viral blood, Capsid immunology, DNA, Viral blood, Herpesvirus 4, Human isolation & purification, Nasopharyngeal Neoplasms virology
- Abstract
We compared the amount of serum Epstein-Barr virus DNA (EBV-DNA) detected in patients with nasopharyngeal carcinoma (NPC) in a high-incidence area, represented by Taiwan, and a low-incidence area, represented by Japan, using real-time quantitative PCR. The median serum EBV-DNA value in 41 Japanese NPC cases was 5450 copies/ml, and that in in 23 Taiwanese cases was 2125 copies/ml. The median serum EBV-DNA value in all 64 NPC cases was significantly higher than in control groups. Using receiver-operating-characteristic (ROC) curves, the sensitivity and specificity of EBV-DNA quantification were determined (cut-off point, 6.87 copies/ml; sensitivity, 0.855; specificity, 0.885) and compared with those of EBV-viral-capsid-antigen (VCA) titers; the results showed that EBV-DNA was a more sensitive and specific parameter than EBV-VCA titer. Then, we analyzed 19 NPC patients in whom recurrence developed (11 Japanese and 8 Taiwanese), and 26 NPC patients in continuous remission. Although there was no significant difference in EBV-DNA values between Japanese and Taiwanese patients, the value was significantly higher in the 19 patients with recurrence than in those in remission. ROC analysis again revealed a higher diagnostic value of EBV-DNA than EBV-VCA. These results suggest EBV-DNA is a more reliable tumor marker than EBV-VCA in both high-incidence and low-incidence areas of NPC.
- Published
- 2004
- Full Text
- View/download PDF